Welcome to our dedicated page for Neuroone Med Technologies news (Ticker: NMTC), a resource for investors and traders seeking the latest updates and insights on Neuroone Med Technologies stock.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) is a medical technology company developing and commercializing minimally invasive, high-definition EEG recording, monitoring, ablation, drug delivery and brain stimulation solutions for neurological disorders. The NMTC news feed on Stock Titan aggregates the company’s latest press releases, conference appearances, product milestones and financial updates so readers can follow how its neuromodulation and surgical technologies are progressing.
Recent news from NeuroOne has included announcements about its OneRF Ablation System, which the company describes as an FDA 510(k)-cleared platform using the same sEEG electrode for both diagnostic and therapeutic applications, and reports of patients achieving seizure reduction or seizure freedom following treatment. The company has also issued news regarding FDA 510(k) clearance for its OneRF Trigeminal Nerve Ablation System for procedures to create radiofrequency lesions for the treatment of pain or for lesioning nerve tissue for functional neurosurgical procedures, highlighting its expansion into facial pain management.
Investors and clinicians can use the NMTC news page to track quarterly and annual financial result announcements, capital raises, updates on regulatory submissions, and developments in programs such as spinal cord stimulation, basivertebral nerve ablation and sEEG-based drug delivery. NeuroOne’s disclosures also cover intellectual property milestones, including notices of allowance for patents related to thin-film electrode and neural probe manufacturing methods, as well as management and advisory appointments intended to support its clinical and commercial strategy.
By reviewing the NMTC news stream, users can see how NeuroOne communicates progress on its technology platform for conditions such as epilepsy, Parkinson’s disease, dystonia, essential tremors and chronic pain due to failed back surgeries, along with the company’s stated plans to explore additional applications. Bookmark this page to access a centralized view of NeuroOne’s official news flow as filed or released to the market.
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced a proposed underwritten public offering of its common stock, intending to use the net proceeds for working capital and general corporate purposes. The offering includes a 30-day option for the underwriter to purchase an additional 15% of the shares sold. The offering is subject to market conditions and may not be completed as planned. Craig-Hallum Capital Group acts as the sole underwriter. The public offering is made under an effective shelf registration statement as filed with the SEC on June 14, 2021.
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced the successful completion of an animal feasibility study for its Evo® ablation electrode, conducted at T3 Labs and Georgia Tech under Dr. Robert Gross. The study demonstrated the ability to record brain activity and ablate tissue, aimed at improving treatment for neurological disorders. The Evo ablation electrode, pending FDA clearance, could allow dual procedures in one hospital visit, enhancing patient care and reducing costs. The company also noted its partnership with RBC Medical for radiofrequency hardware development.
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference, taking place virtually from September 13-15, 2021. The presentation will be available on-demand starting September 13. Management will also conduct one-on-one investor meetings during the event. NeuroOne focuses on innovative surgical solutions for neurological disorders, having received FDA clearance for its Evo cortical and sEEG electrode technologies. The company aims to improve patient outcomes and reduce costs.
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced FDA 510(k) clearance for its Evo sEEG Electrode technology, designed for temporary use in recording, monitoring, and stimulating subsurface brain signals. This product is the second FDA-cleared device for the company, tapping into a $100 million market for brain mapping. NeuroOne aims to expand sEEG labeling for longer-term use and develop therapeutic electrodes for chronic conditions, with an estimated addressable market between $500 million and $6 billion. The company anticipates being launch-ready by the end of 2021.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) was featured on Cheddar News, discussing advancements in their brain implant technology aimed at improving treatment for neurological disorders. CEO Dave Rosa highlighted the unique high-definition capabilities of their sEEG electrodes, offering 900 contact points compared to traditional electrodes, which enhance precision and clarity. The company aims to integrate multiple functions into one device, reducing the need for multiple surgeries. NeuroOne's partnerships with major medical entities enhance its development efforts, focusing on conditions like epilepsy and Parkinson's disease.
NeuroOne Medical Technologies Corporation (NMTC) has partnered with RBC Medical Innovations to develop a proprietary radiofrequency generator, aiming to innovate seizure treatment. This partnership combines diagnostic and therapeutic functions into a single electrode, simplifying the process for patients with epilepsy or brain tumors. This advancement is set to save time and costs while potentially improving outcomes. The market for this innovation is projected to exceed $100M. Completion of the project is anticipated by late 2022, pending regulatory clearance.
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced its third quarter financial results for fiscal 2021, achieving product revenue of $40,000 and collaboration revenue of $17,000, a notable increase from zero revenue in the same quarter last year. Operating expenses totaled $3.0 million, with a net loss of $3.0 million, improved from a net loss of $7.1 million in the prior year. The company completed its first human use of the Evo Cortical electrode at Mayo Clinic and closed a $12.5 million private placement. NeuroOne is on track for further product launches and has uplisted to Nasdaq.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) will host a conference call on August 13, 2021, at 9:00 AM ET to discuss its financial results for the third quarter ended June 30, 2021. The company focuses on innovative surgical solutions for neurological disorders. Notably, NeuroOne successfully achieved its first performance milestone in a partnership with Zimmer Biomet, securing exclusive global distribution rights for its Evo™ patented electrode technology. The company has received FDA clearance for this technology in November 2019.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced its participation in the Alliance Global Partners Virtual MedTech Summer Conference on July 29, 2021. The event will feature one-on-one virtual meetings between investors and management. NeuroOne focuses on developing advanced EEG recording and ablation solutions for neurological disorders like epilepsy and Parkinson's disease. The company recently achieved a key milestone in its distribution agreement with Zimmer Biomet, further enhancing its market position.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) will present at the Access to Giving Virtual Conference on July 15, 2021, at 2 p.m. ET. The conference aims to connect companies with investors for fundraising opportunities. NeuroOne focuses on innovative solutions for neurological disorders, including epilepsy and Parkinson's disease, leveraging patented electrode technology. The company previously achieved a performance milestone with Zimmer Biomet and received FDA clearance for its Evo cortical technology in November 2019. For more details, visit n1mtc.com.
FAQ
What is the current stock price of Neuroone Med Technologies (NMTC)?
What is the market cap of Neuroone Med Technologies (NMTC)?
